Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC).

被引：13
|
作者：
Shah, Manish A.
Almhanna, Khaldoun
Iqbal, Syma
Thakkar, Prashant
Schneider, Bryan J.
Yantiss, Rhonda
Wu, Yiru
Futamura, Emma
Port, Jeffrey L.
Spinelli, Cathy
Sarkar, Sandipto
Christos, Paul J.
Brar, Gagandeep
Betel, Doron
Sanfilippo, Nicholas J.
Altorki, Nasser K.
机构：
[1] Weill Cornell Med, New York, NY USA
[2] Lifespan, Providence, RI USA
[3] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[4] Weill Cornell Med Coll, New York Presbyterian Hosp, New York, NY USA
[5] Weill Cornell Med, New York, NY USA
[6] Weill Cornell, New York, NY USA
[7] Lifespan Canc Inst, Providence, RI USA
[8] Cornell Univ, Weill Med Coll, New York, NY USA
[9] Weill Cornell Med Coll, New York, NY USA
[10] Weill Cornell Med Coll, Dept Biostat & Epidemiol, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4005
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II study of neoadjuvant and adjuvant gefitinib (G) with neoadjuvant chemoradiotherapy (CRT) in operable esophageal adenocarcinoma (EAC)
    Juergens, R. A.
    Gibson, M. K.
    Yang, S. C.
    Brock, M.
    Heitmiller, R.
    Tsottles, N.
    Rudek, M. A.
    Canto, M.
    Kleinberg, L.
    Forastiere, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Is Neoadjuvant Chemoradiotherapy Superior to Neoadjuvant Chemotherapy in Resectable Esophageal Adenocarcinoma?
    Prescott, A. T.
    Koshenkov, V. P.
    Koru-Sengul, T.
    Freiser, M. E.
    Rosati, C.
    Sparling, J. L.
    Allan, B. J.
    Franceschi, D.
    Livingstone, A.
    Avisar, E.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S108 - S108
  • [3] Neoadjuvant Chemoradiotherapy Versus Chemotherapy for the Treatment of Locally Advanced Esophageal Adenocarcinoma in the European Multicenter ENSURE Study
    Elliott, Jessie A.
    Klevebro, Fredrik
    Mantziari, Styliani
    Markar, Sheraz R.
    Goense, Lucas
    Johar, Asif
    Lagergren, Pernilla
    Zaninotto, Giovanni
    van Hillegersberg, Richard
    Henegouwen, Mark I. van Berge
    Schafer, Markus
    Nilsson, Magnus
    Hanna, George B.
    Reynolds, John V.
    ANNALS OF SURGERY, 2023, 278 (05) : 692 - 700
  • [4] A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared with Chemoradiotherapy in Locally Advanced Gastric Adenocarcinoma
    Wang, X.
    Jin, J.
    Zhao, D. B.
    Chi, Y. H. B. L.
    Yang, L.
    Jiang, L.
    Dou, L. Z.
    Tang, Y.
    Li, N.
    Liu, W., Jr.
    Tian, Y. T.
    Zhao, H.
    Che, X.
    Bai, X. F.
    Lu, N.
    Hua, R.
    Fang, H.
    Wang, S. L.
    Song, Y. W.
    Liu, Y.
    Li, Y. X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S29 - S30
  • [5] Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal adenocarcinoma
    Goense, L.
    Van der Sluis, P. C.
    Van Rossum, P. S. N.
    Van der Horst, S.
    Van Vulpen, M.
    Mook, S.
    Ruurda, J. P.
    Van Hillegersberg, R.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S328 - S328
  • [6] A randomized phase II trial of neoadjuvant chemotherapy compared with chemoradiotherapy in locally advanced gastroesophageal and gastric adenocarcinoma
    Jin, J.
    Wang, X.
    Zhao, D. B.
    Chi, Y.
    Zhao, H.
    Yang, L.
    Zhou, A. P.
    Jiang, L. M.
    Tang, Y.
    Ren, H.
    Li, N.
    Liu, W. Y.
    Li, Y. X.
    ANNALS OF ONCOLOGY, 2015, 26 : 69 - 69
  • [7] Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal cancer
    Cheng, X.
    Chen, Y.
    Wu, X.
    Hao, D.
    Zhang, Y.
    Li, X.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] THE IMPACT OF PATHOLOGICAL TUMOR RESPONSE FOLLOWING NEOADJUVANT CHEMOTHERAPY AND CHEMORADIOTHERAPY FOR ESOPHAGEAL ADENOCARCINOMA. A RETROSPECTIVE MULTICENTER COHORT STUDY
    Capovilla, Giovanni
    Scarton, Alessia
    Sciuto, Elisa
    Moletta, Lucia
    Pierobon, Elisa Sefora
    Zanchettin, Gianpietro
    Riccio, Federica
    Provenzano, Luca
    Salvador, Renato
    Berlth, Felix
    Tagkalos, Evangelos
    Uzun, Eren
    De Pasqual, Carlo Alberto
    Turolo, Cecilia
    Weindelmayer, Jacopo
    Giacopuzzi, Simone
    De Manzoni, Giovanni
    Grimminger, Peter P.
    Valmasoni, Michele
    GASTROENTEROLOGY, 2024, 166 (05) : S1838 - S1839
  • [9] Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study
    Guo, Jhe-Cyuan
    Huang, Ta-Chen
    Kuo, Hung-Yang
    Lin, Chia-Chi
    Hsu, Feng-Ming
    Cheng, Jason Chia-Hsien
    Huang, Yen-Lin
    Hsieh, Min-Shu
    Huang, Pei-Ming
    Lee, Jang-Ming
    Wu, Shu-Ling
    Hsu, Chih-Hung
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (11)
  • [10] Phase II study of irinotecan plus panitumumab as second-line therapy for patients with advanced esophageal adenocarcinoma (EAC)
    Atasoy, A.
    Yoon, H.
    Egloff, A. M.
    Ferris, R. L.
    Zaidi, A. H.
    Hough, B.
    Forastiere, A. A.
    Jobe, B. A.
    Nason, K. S.
    Gibson, M. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345